Featured image for ACOG Endorses 2026 WPSI Cervical Cancer Screening Guidelines

In a new ACOG Committee Statement, the American College of Obstetricians & Gynecologists endorses the 2026 Women’s Preventive Services Initiative (WPSI) cervical cancer screening recommendations, adopted by the Health Resources & Services Administration (HRSA), with specific qualifications—particularly regarding patient-collected high-risk human papillomavirus (hrHPV) testing.

  • Age 21–29 years: Continue cervical cytology alone every 3 years. No changes from prior guidance.
  • Age 30–65 years: Clinician-collected primary hrHPV screening every 5 years using U.S. Food and Drug Administration-approved tests is now the preferred strategy. Co-testing every 5 years remains acceptable when primary hrHPV testing is unavailable or after patient counseling.
  • Patient-collected hrHPV testing: May be considered every 3 years for patients aged 30–65 years using clinician-ordered, U.S. Food and Drug Administration-approved kits, provided systems for documentation, notification, and follow-up are in place. ACOG recommends a 3-year interval due to insufficient data supporting a 5-year cadence for self-collection.
  • Age >65 years and post-hysterectomy: Routine screening is not clinically indicated in patients older than 65 years with adequate prior screening (three consecutive negative cytology results or two consecutive negative co-tests within 10 years, with the most recent within 3–5 years) or in those who have undergone hysterectomy with removal of the cervix and no history of cervical cancer or high-grade precancer.